UT Southwestern Medical Center researchers have discovered that knocking down microRNA-208a in the heart leads to systemic benefits in obesity and metabolic diseases. The findings could expand the potential indications for miRagen's antimiR-208, which is in preclinical development for cardiac hypertrophy.